ZA885929B - Agents for use in tumor or cancer cell killing therapy - Google Patents

Agents for use in tumor or cancer cell killing therapy

Info

Publication number
ZA885929B
ZA885929B ZA885929A ZA885929A ZA885929B ZA 885929 B ZA885929 B ZA 885929B ZA 885929 A ZA885929 A ZA 885929A ZA 885929 A ZA885929 A ZA 885929A ZA 885929 B ZA885929 B ZA 885929B
Authority
ZA
South Africa
Prior art keywords
tumor
agents
administration
radiation
compound
Prior art date
Application number
ZA885929A
Other languages
English (en)
Inventor
Ronald W Pero
W Pero Ronald
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Priority to ZA886755A priority Critical patent/ZA886755B/xx
Publication of ZA885929B publication Critical patent/ZA885929B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA885929A 1987-08-25 1988-08-11 Agents for use in tumor or cancer cell killing therapy ZA885929B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA886755A ZA886755B (en) 1988-08-11 1988-09-09 A flameproofing agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8947787A 1987-08-25 1987-08-25

Publications (1)

Publication Number Publication Date
ZA885929B true ZA885929B (en) 1989-04-26

Family

ID=22217866

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA885929A ZA885929B (en) 1987-08-25 1988-08-11 Agents for use in tumor or cancer cell killing therapy

Country Status (13)

Country Link
US (1) US5340565A (ja)
EP (1) EP0305008B1 (ja)
JP (1) JP2767590B2 (ja)
AT (1) ATE106749T1 (ja)
AU (1) AU622118B2 (ja)
CA (1) CA1336409C (ja)
DE (1) DE3850007T2 (ja)
DK (1) DK474688A (ja)
ES (1) ES2056902T3 (ja)
IE (1) IE63858B1 (ja)
IL (1) IL87525A (ja)
RU (1) RU2080115C1 (ja)
ZA (1) ZA885929B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
IT1252126B (it) * 1991-11-22 1995-06-05 Ist Naz Ric Sul Cancro Triamino platino complessi e loro metodo di sintesi
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US6056960A (en) * 1995-06-07 2000-05-02 Kaslow; Harvey R. Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
US6028111A (en) * 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6713517B1 (en) * 1996-03-08 2004-03-30 Oxigene, Inc. Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use
AU6165798A (en) * 1997-02-18 1998-09-08 Bridge Pharma, Inc. Non-sedating histamine antagonist compounds, compositions and methods of use thereof
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
US6448288B1 (en) * 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
EP1345917A1 (en) * 2000-12-19 2003-09-24 Ucb, S.A. 2-(2-(4-((2r)-2-methyl-3-(10h-phenothiazin-10-yl)propyl)-1-piperazinyl)-ethoxy)ethanol, process for the preparation thereof, pharmaceutical compositions containing said compound and therapeutic uses thereof
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
US7547716B2 (en) 2001-06-08 2009-06-16 Institute Of Medicinal Molecular Design, Inc. Sulfonamide derivatives
WO2010025135A2 (en) * 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
FR2970965A1 (fr) * 2011-01-31 2012-08-03 Centre Nat Rech Scient Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation
EP2825173B1 (en) 2012-03-16 2018-10-10 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536386B1 (en) * 1981-01-26 1995-03-07 Robins Co Inc A H Method of controlling emesis caused by cisplatin in cancer chemotherapy
US5081153A (en) * 1984-05-17 1992-01-14 Beecham Group P.L.C. Sterile parenteral composition

Also Published As

Publication number Publication date
RU2080115C1 (ru) 1997-05-27
ES2056902T3 (es) 1994-10-16
CA1336409C (en) 1995-07-25
IE882487L (en) 1989-02-25
EP0305008A2 (en) 1989-03-01
DE3850007D1 (de) 1994-07-14
JP2767590B2 (ja) 1998-06-18
US5340565A (en) 1994-08-23
AU622118B2 (en) 1992-04-02
AU2150888A (en) 1989-03-02
DK474688A (da) 1989-02-26
IL87525A0 (en) 1989-01-31
EP0305008B1 (en) 1994-06-08
IE63858B1 (en) 1995-06-14
JPH0196122A (ja) 1989-04-14
DK474688D0 (da) 1988-08-25
DE3850007T2 (de) 1994-09-22
EP0305008A3 (en) 1990-05-16
IL87525A (en) 1994-05-30
ATE106749T1 (de) 1994-06-15

Similar Documents

Publication Publication Date Title
ZA885929B (en) Agents for use in tumor or cancer cell killing therapy
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
Breithaupt et al. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules
GEP20022786B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and 1kB-a
ZA928771B (en) Combination chemotherapy
EP0430045A3 (en) Ascorbic acid tocopheryl phosphate diesters for inhibition of maillard's reaction
DE3376295D1 (en) Pharmaceutical composition containing adenosine derivatives for use in treating tumours
EP0211354A3 (en) Nucleosides and their use as antineoplastic agents
Ben-Hur Involvement of poly (ADP-ribose) in the radiation response of mammalian cells
JPS5735516A (en) Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
Griswold Jr et al. ALTERED SENSITIVITY OF A HAMSTER PLASMACYTOMA TO CYTOSINE ARABINOSIDE (NSC-63878) 1.2. 3
SE8303003L (sv) Medel for att oka antitumorverkan hos antitumormedel
Liesmann et al. Phase I evaluation of ICRF‐187 (NSC‐169780) in patients with advanced malignancy
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
Murley et al. Chemoprevention with WR-2721 and its metabolites
Baguley et al. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine
Leopold et al. Chemical approaches to improved radiotherapy
Valeriote et al. Dose and interval relationship for the interaction of WR-2721 and nitrogen mustard with normal and malignant cells
HK1032204A1 (en) Composition containing propargylamine for enhancing cancer therapy
Rosenthal et al. Potentiation of DNA damage and cytotoxicity by calmodulin antagonists.
Jorgensen et al. Pilot study evaluating 1, 3-bis (2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma
Kjellén et al. Effect of hyperthermia and/or nicotinamide on the radiation response of a C3H mammary carcinoma
Bierman MEDICAL PROGRESS: NEWER METHODS OF TREATMENT OF LEUKEMIAS AND LYMPHOMAS